Search Results for “artificial intelligence” – Page 6 – media

1.774 billion, Mindray has big moves

Recently, the “Maidong Technology Park”, which is the global headquarters base of Mindray Animal Medical, officially started construction in Longhua, Shenzhen. It is reported that the land for the Maidong Technology Park project will be sold in September 2023, covering an area of 58600 square meters and a building area of 176000 square meters. The total planned investment is 1.774 billion yuan. After completion, it will create an intelligent manufacturing “black light” factory with high-precision automation equipment covering the entire area. Through automatic and intelligent on-site logistics scheduling, efficient, high-quality, and low-cost manufacturing will be achieved. 01. Expected annual output value exceeds 12 billion In recent years, Mindray Medical has begun to focus on four emerging businesses, namely animal medicine, minimally invasive surgery, orthopedics, and AED, on the basis of its traditional three core businesses. In 2022, Li Xiting, Chairman of Mindray Medical, made a statement Animal medicine is a ...
- Source: drugdu
- 59
- October 26, 2024
SenseTime may initiate large-scale layoffs

On October 22nd, Xu Li, Chairman and CEO of SenseTime Technology, sent a letter to all employees, establishing the three in one strategy of “large equipment large model application”, which was mentioned for the first time. After the release of the full staff letter by SenseTime Technology, organizational adjustments and layoffs were immediately initiated, with a focus on retaining the two businesses related to the RiRiXin large model and large equipment. The remaining business lines, including security, autonomous driving, medical, etc., began to be adjusted, and the compensation given was N+1. On October 23rd, in response to the online rumors of layoffs, SenseTime Technology stated that it is actively promoting strategic transformation, focusing on key business and strategic growth areas of “large equipment large model application”, and optimizing and adjusting its organizational and talent structure to better meet business development needs. At present, SenseTime’s social recruitment and campus recruitment are ...
- Source: drugdu
- 64
- October 26, 2024
1.596 billion, this pharmaceutical company was acquired

On the evening of October 21, Sichuan Shuangma announced that it plans to use its own and self-raised funds to acquire 92.1745% of Jianyuan Pharmaceutical’s equity for a total of 1.596 billion yuan. On October 22, Sichuan Shuangma opened at the daily limit, with a total market value of more than 14.3 billion yuan. Sichuan Shuangma was formerly known as Sichuan Shuangma Cement Co., Ltd. It was initially a building materials company focusing on the production and sales of cement products and building aggregates. It was listed on the main board of the Shenzhen Stock Exchange in 1999, and then gradually developed into a listed company engaged in industrial investment and private equity investment fund management. Its main managed assets include building materials manufacturing companies and private equity investment fund management companies. Sichuan Shuangma, born in the traditional industry, has not been optimistic about its recent development. The financial report ...
- Source: drugdu
- 59
- October 26, 2024
AI+drug target discovery | Insitro and Eli Lilly reach strategic agreement to jointly promote new therapies for metabolic diseases

Zhiyao Bang October 23, 2024 09:01 Shanghai On October 9, 2024, insitro, a new drug development company that supports machine learning, announced the signing of three strategic agreements with Eli Lilly, focusing on developing potential new drugs for the treatment of metabolic diseases, including metabolic dysfunction associated fatty liver (MASLD), based on the targets identified by insitro using the company’s AI based platform.Metabolic diseases, including MASLD, affect millions of people worldwide, but effective treatment options are still limited. The current treatment mainly treats the symptoms rather than the root cause. This collaboration aims to combine Insitro’s machine learning platform with Lilly’s expertise in cutting-edge drug delivery and metabolic disease biology to change existing models. According to the first two agreements, Insitro can choose to license Lilly’s proprietary, clinically advanced ternary N-acetylglucosamine (GalNAc) delivery technology, which will be combined with two different small interfering RNA (siRNA) molecules discovered and developed by ...
- Source: drugdu
- 74
- October 24, 2024
Another “hundred-ton” synthetic biology production line was successfully delivered, 60 million yuan!

On September 23, the food additive synthetic biology production line project of the biotechnology company undertaken by Sanxi Group successfully completed all installation and commissioning work and was delivered on schedule, which marked that the project has fully entered the production and operation stage. It is reported that the total investment of the production line is about 60 million yuan, and it is equipped with 4 fully automatic precision fermentation production lines. These production lines are equipped with advanced automated separation and purification systems, which can monitor various key parameters in the production process in real time to ensure comprehensive, efficient and precise control of product quality. The successful delivery of this project not only demonstrates Sanxi Group’s deep technical accumulation in the field of synthetic biology equipment manufacturing, but also reflects its efficient project management and delivery capabilities. In recent years, with the continuous development of technologies such as ...
- Source: drugdu
- 60
- October 17, 2024
Partners with 10 Indian AI Startups

Novo Nordisk recently partnered with 10 Indian artificial intelligence (AI) startups, marking an important moment for the Indian AI ecosystem. The Danish company, best known for its weight loss drug Wegovy, is leveraging AI innovations to streamline operations and improve efficiency. The moves are part of the Danish drugmaker’s expansion plans for operations in Bangalore, which it opened 17 years ago. The center helps manage the vast amounts of data collected about the safety and effectiveness of its drugs, including clinical trial information and reports of potential side effects. One of the factors driving the move is that demand for obesity and diabetes-related drugs is expected to grow, especially as global attention to these health issues grows. By strategically positioning itself in India, one of the world’s largest markets for diabetes drugs, Novo Nordisk expects to meet the growing demand by increasing its production capacity. The partnership also has a ...
- Source: drugdu
- 64
- October 17, 2024
Collaborating with 10 Indian AI startups

These measures are part of the business expansion plan launched by this Danish pharmaceutical company in Bangalore 17 years ago. The center helps manage a large amount of data collected regarding the safety and efficacy of its drugs, including clinical trial information and potential side effect reports. One of the factors driving this initiative is that the demand for obesity and diabetes related drugs is expected to grow, especially with the increasing global attention to these health problems. Through strategic positioning in India (one of the world’s largest diabetes drug markets), Novo Nordisk is expected to meet the growing demand by improving its production capacity. This partnership has also had a broader impact on the operations of Novo Nordisk. It is expected that Novo Nordisk’s Bangalore center will become an approximate mirror of its Danish headquarters within three years. The company plans to increase the number of employees in Bangalore ...
- Source: drugdu
- 62
- October 16, 2024
Sanxi Group’s Synthetic Biology Production Line is Delivered as Scheduled

It is reported that the total investment of the production line is about 60 million yuan, and it is equipped with four fully automatic precision fermentation production lines. These production lines are all equipped with advanced automated separation and purification systems, which can monitor various key parameters in the production process in real time, ensuring comprehensive, efficient, and precise control of product quality. The successful delivery of this project not only demonstrates Sanxi Group’s profound technical accumulation in the field of synthetic biological equipment manufacturing, but also demonstrates its efficient project management and delivery capabilities. In recent years, with the continuous development of technologies such as gene editing and artificial intelligence, synthetic biology has sparked a new wave of research. Scientists have high hopes for this cutting-edge science, hoping to use this technology to improve human health, address food crises, alleviate global warming and other common problems faced by humanity. ...
- Source: drugdu
- 63
- October 15, 2024
intensified BD trading competition in the pharmaceutical market, pharmaceutical companies launch market competition war

Source: 21st Century Business Herald Has the cow arrived? The A-share market is booming, don’t miss the opportunity, open an account and layout now>> Recently, there has been a frequent wave of business development (BD) cooperation transactions between Chinese and foreign pharmaceutical companies. On October 9th, Baiaotai announced that it has reached an authorization license, production, supply, and commercialization agreement with Gedeon Richter Plc. for BAT2206 (ustekinumab) injection solution. According to the agreement, Baiaotai will license the exclusive commercial rights of the injection in the EU, UK, Switzerland, Australia, and other European markets to Gedeon Richter Plc for a fee. The amount involved in this transaction includes a down payment of $8.5 million, milestone payments up to a cumulative total of $101.5 million, and revenue sharing based on a double-digit percentage of net sales. In addition to Baiaotai, several Chinese pharmaceutical companies have also recently received positive news regarding BD ...
- Source: drugdu
- 87
- October 12, 2024
14.1 billion, Johnson&Johnson announces big move

On October 9th, Johnson&Johnson announced plans to invest over $2 billion (approximately RMB 14.1 billion) in Wilson, North Carolina to build an advanced biopharmaceutical manufacturing facility to support its growing portfolio of biologic therapy products in oncology, immunology, and neuroscience. It is reported that this measure is in line with Johnson&Johnson’s broader strategy of submitting or launching over 70 new therapies and product expansions by the end of the next decade. The new facility will be equipped with cutting-edge technology, which will not only enhance global production capacity, but also provide approximately 420 high skilled full-time positions for the local area. The project will begin construction in the first half of 2025. In August of this year, in order to strengthen its position in the cardiovascular field, Johnson&Johnson announced the acquisition of V-Wave, a company specializing in heart failure treatment technology. Prior to this, Johnson&Johnson acquired for approximately $13.1 billion ...
- Source: drugdu
- 75
- October 12, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.